Nicole Faust, PhD, CEVEC Pharmaceuticals, Koeln, Germany, discusses the potential impact of the COVID-19 pandemic on the regulation of gene therapies. The use of gene therapy technologies in the development of vaccines for COVID-19 and their administration in a large number of people is expected to improve understanding on the use and safety of gene therapies. In addition, experience gained from their wide-scale manufacture and the knowledge obtained on chemistry, manufacturing, and controls (CMC) processes will likely facilitate the regulation of gene therapies in the future and potentially lead to more rapid approvals. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.
Nicole Faust is an employee of CEVEC Pharmaceuticals, Koeln, Germany.